NCT00709514 is a Phase 2 clinical trial of DCB-WH1 ointment in Chronic Diabetic Foot Ulcer, sponsored by Oneness Biotech Co., Ltd..

Who is sponsoring NCT00709514?

NCT00709514 is sponsored by Oneness Biotech Co., Ltd..

What drugs are being tested in NCT00709514?

Interventions in NCT00709514: DCB-WH1 ointment, Placebo.

What condition does NCT00709514 study?

NCT00709514 studies Chronic Diabetic Foot Ulcer.

Is NCT00709514 still recruiting?

NCT00709514 is currently completed. Last updated 8 July 2013.

Last reviewed 2013-07-08 · How we verify

NCT00709514

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II, Double-blind, Placebo-controlled Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers

Completed Phase 2 Last updated 8 July 2013

What this trial tests

Phase 2 trial testing DCB-WH1 ointment in Chronic Diabetic Foot Ulcer in 41 participants. Completed in 1 March 2012.

Timeline

1 December 2008

Primary endpoint
1 April 2011

1 March 2012

Quick facts

Lead sponsor	Oneness Biotech Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	41
Start date	1 December 2008
Primary completion	1 April 2011
Estimated completion	1 March 2012
Sites	1 location across Taiwan

Drugs / interventions tested

DCB-WH1 ointment — full drug profile →
Placebo

Conditions studied

Chronic Diabetic Foot Ulcer — all drugs for Chronic Diabetic Foot Ulcer →

Sponsor

Oneness Biotech Co., Ltd. — full company profile →

Who can join

20 and older, any sex, with Chronic Diabetic Foot Ulcer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The incidence of complete ulcer closure
Time frame: 12 weeks

Sponsor's own description

The primary objective of this Phase 2 study is to evaluate the efficacy of DCB-WH1 ointment in wound closure as compared to vehicle control when applied topically to chronic diabetic foot ulcers for 12 weeks. The secondary objective of this study is to collect safety information of DCB-WH1 ointment. This is a randomized, double-blind, parallel group, vehicle-controlled, multi-center study of DCB-WH1 ointment applied topically to grade 1 foot ulcers (according to Wagner grading system) in 50 subjects with diabetes mellitus.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Growth factors for treating diabetic foot ulcers.
Martí-Carvajal AJ, Gluud C, Nicola S, Simancas-Racines D, et al · · 2015 · cited 94× · PMID 26509249 · DOI 10.1002/14651858.cd008548.pub2
Plectranthus amboinicus and Centella asiatica Cream for the Treatment of Diabetic Foot Ulcers.
Kuo YS, Chien HF, Lu W. · · 2012 · cited 26× · PMID 22693530 · DOI 10.1155/2012/418679

Verify or expand the search:

Other Oneness Biotech Co., Ltd. trials

Trials by the same sponsor.

NCT06397911 — Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis · Phase 2 · recruiting
NCT05941793 — A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients · Phase 2 · completed
NCT05952986 — A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults · Phase 1 · unknown
NCT05677893 — A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inh · Phase 1 · completed
NCT05438251 — Exploring the Effect of Fespixon Cream for the Treatment of Diabetic Foot Ulcers (TEXAS 3A, 3B) · Phase 4 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00709514 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oneness Biotech Co., Ltd.
Last refreshed: 8 July 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00709514.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing